Investig Clin Urol.  2016 Jun;57(Suppl 1):S1-S3. 10.4111/icu.2016.57.S1.S1.

Changing landscape of diagnosis and treatment of bladder cancer

• Kim WJ

• KMID: 2426511
• DOI: http://doi.org/10.4111/icu.2016.57.S1.S1

Abstract

No abstract available.

MeSH Terms

Humans
Urinary Bladder Neoplasms/*diagnosis/etiology/*therapy

Reference

1. Miyake M, Fujimoto K, Hirao Y. Active surveillance for nonmuscle invasive bladder cancer. Investig Clin Urol. 2016; 57:Suppl 1. S4–S13.

2. Piyathilake C. Dietary factors associated with bladder cancer. Investig Clin Urol. 2016; 57:Suppl 1. S14–S25.

3. Erlich A, Zlotta AR. Treatment of bladder cancer in the elderly. Investig Clin Urol. 2016; 57:Suppl 1. S26–S35.

4. Davis RB, Farber NJ, Tabakin AL, Kim IY, Elsamra SE. Open versus robotic cystectomy: comparison of outcomes. Investig Clin Urol. 2016; 57:Suppl 1. S36–S43.

5. Yun SJ, Kim SK, Kim WJ. How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy? Investig Clin Urol. 2016; 57:Suppl 1. S44–S51.

6. Lee JY, Ryu DS, Kim WJ, Kim SJ. Aberrantly expressed microRNAs in the context of bladder tumorigenesis. Investig Clin Urol. 2016; 57:Suppl 1. S52–S59.

7. Enokida H, Yoshino H, Matsushita R, Nakagawa M. The role of microRNAs in bladder cancer. Investig Clin Urol. 2016; 57:Suppl 1. S60–S76.

8. Kim YJ, Kim WJ. Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer? Investig Clin Urol. 2016; 57:Suppl 1. S77–S88.

9. Chandrasekar T, Evans CP. Autophagy and urothelial carcinoma of the bladder: a review. Investig Clin Urol. 2016; 57:Suppl 1. S89–S97.

10. Kim J. Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol. 2016; 57:Suppl 1. S98–105.